Recombinant protective antigen anthrax vaccine (SparVax, PharmAthene)

N/A

Report date: 2022/07/19 16:22:54

Base Information

Drug NameRecombinant protective antigen anthrax vaccine (SparVax, PharmAthene)
Drug Alias NamerPA anthrax vaccine (SparVax) - AltimmuneRecombinant PA anthrax vaccine - AltimmuneSecond-generation rPA vaccine - AltimmuneSparVaxrPA vaccine containing alhydrogel - Altimmune +[6] 
ClassificationVaccines > Application > Prophylactic vaccineVaccines > Development/production technology > Genetically engineered subunit vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsAnthrax
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAltimmune Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPharmathene Uk Ltd
Active IndicationsN/A
Inactive IndicationsAnthrax

Other Information

ATC CodeN/A
Related LinksN/A